In Q2 2026, OPKO Health posted revenue exceeding expectations driven by its long-acting Somatrogon pharmaceutical approvals across major markets and robust diagnostic segment performance. Despite the revenue upside, the company remains unprofitable due to high R&D expenses and operational costs underlying product launches and pipeline advancement. The diversified portfolio, including BioReference diagnostics and partner-launched Mazdutide, provides revenue stability amid biopharma development risk. However, sustaining liquidity beyond current cash reserves will depend on execution of commercial initiatives and potential capital raises, given ongoing net losses and contractual obligations.